Next Article in Journal
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
Next Article in Special Issue
Flavopereirine Suppresses the Growth of Colorectal Cancer Cells through P53 Signaling Dependence
Previous Article in Journal
LdrB Toxin with In Vitro and In Vivo Antitumor Activity as a Potential Tool for Cancer Gene Therapy
Previous Article in Special Issue
Genetic Aberration Analysis in Thai Colorectal Adenoma and Early-Stage Adenocarcinoma Patients by Whole-Exome Sequencing
Open AccessReview

The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer

1
CEINGE-Biotecnologie Avanzate s.c.ar.l., 80145 Naples, Italy
2
Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, 80131 Naples, Italy
3
Team of Metabolism, Cancer & Immunity, Centre de Recherche des Cordeliers, UMRS1138, Université Paris Descartes, Sorbonne Université, Université Paris Diderot, 75006 Paris, France
4
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94805 Villejuif, France
5
Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique—Hôpitaux de Paris, 75015 Paris, France
6
Department of Women’s and Children’s Health, Karolinska Institute, Karolinska University Hospital, 17176 Stockholm, Sweden
*
Authors to whom correspondence should be addressed.
Cancers 2019, 11(7), 1017; https://doi.org/10.3390/cancers11071017
Received: 11 June 2019 / Revised: 15 July 2019 / Accepted: 19 July 2019 / Published: 20 July 2019
(This article belongs to the Special Issue Colorectal Cancers)
Colorectal cancer (CRC) is a leading cause of cancer death worldwide. It includes different subtypes that differ in their clinical and prognostic features. In the past decade, in addition to the conventional adenoma-carcinoma model, an alternative multistep mechanism of carcinogenesis, namely the “serrated pathway”, has been described. Approximately, 15 to 30% of all CRCs arise from neoplastic serrated polyps, a heterogeneous group of lesions that are histologically classified into three morphologic categories: hyperplastic polyps, sessile serrated adenomas/polyps, and the traditional serrated adenomas/polyps. Serrated polyps are characterized by genetic (BRAF or KRAS mutations) and epigenetic (CpG island methylator phenotype (CIMP)) alterations that cooperate to initiate and drive malignant transformation from normal colon mucosa to polyps, and then to CRC. The high heterogeneity of the serrated lesions renders their diagnostic and pathological interpretation difficult. Hence, novel genetic and epigenetic biomarkers are required for better classification and management of CRCs. To date, several molecular alterations have been associated with the serrated polyp-CRC sequence. In addition, the gut microbiota is emerging as a contributor to/modulator of the serrated pathway. This review summarizes the state of the art of the genetic, epigenetic and microbiota signatures associated with serrated CRCs, together with their clinical implications. View Full-Text
Keywords: colorectal cancer; serrated pathway; serrated lesions; serrated polyp; CIMP; DNA methylation; MSI; CIN; serrated adenocarcinoma; gut microbiota colorectal cancer; serrated pathway; serrated lesions; serrated polyp; CIMP; DNA methylation; MSI; CIN; serrated adenocarcinoma; gut microbiota
Show Figures

Graphical abstract

MDPI and ACS Style

De Palma, F.D.E.; D’Argenio, V.; Pol, J.; Kroemer, G.; Maiuri, M.C.; Salvatore, F. The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer. Cancers 2019, 11, 1017.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop